News | Brachytherapy Systems | April 18, 2019

Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms

New study evaluated combination of maximum safe resection with surgically-guided collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms

Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms

April 18, 2019 — Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on surgically targeted radiation therapy for previously irradiated intracranial neoplasms during the 2019 American Association of Neurological Surgeons (AANS) annual scientific meeting, April 13-17 in San Diego. Nakaji’s research was the winner of the Mahaley Clinical Research Award.

Resection alone is typically insufficient for recurrent, previously irradiated intracranial neoplasms and repeat adjuvant external beam radiation treatment (EBRT) is often contraindicated. For these reasons, researchers prospectively evaluated the combination of maximum safe resection (R) and surgically guided collagen tile brachytherapy (TBT) in this cohort of patients. This study differed from older studies in that the isotope used, Cesium 131, has a shorter half-life than that used a generation ago, and the brachytherapy seed spacing is achieved by imbedding the sources in a collagen carrier.

According to researchers, "We believe that this new technology is fundamentally different from the older brachytherapy studies in both the isotope and the spacing, and this is what has given us our favorable results across a range of tumor types.”

At the end of the study, it was found that surgically targeted tile brachytherapy exhibited good site local control (LC) and overall survival (OS) with complication rates comparable to existing treatments. This study adds to recent studies supporting the use of brachytherapy for neurosurgical disease. This treatment could expand the therapeutic options for this difficult cohort of patients.

For more information: www.aans.org

Related Content

Vinai Gondi, M.D., the Director of Research at the Northwestern Medicine Chicago Proton Center, Co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

Vinai Gondi, M.D., director of research at the Northwestern Medicine Chicago Proton Center, co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

News | Intensity Modulated Radiation Therapy (IMRT) | October 27, 2020
October 27, 2020 — A...
"Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial" was presented by Jing Li, M.D., The University of Texas MD Anderson Cancer Center, at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — Results of a new randomized phase III trial suggest that...
"Stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung: A randomised phase II trial," presented by Shankar Siva, Ph.D., Peter MacCallum Cancer Centre, was presented at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — A new study, conducted across 13 medical centers in Australia and New Zealand, strengthens the cas
"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer" was presented by Ashesh Jani, M.D., Winship Cancer Institute of Emory University, at ASTRO20
News | PET Imaging | October 26, 2020
October 26, 2020 — Adding the advanced PET radiotracer...
A randomized phase II/III study comparing 24Gy in 2 stereotactic body radiotherapy (SBRT) fractions versus 20Gy in 5 conventional palliative radiotherapy (CRT) fractions for patients with painful spinal metastases was presented by Arjun Sahgal, M.D., University of Toronto, today at ASTRO20
News | Radiation Therapy | October 26, 2020
October 26, 2020 — A new study shows using fewer and higher doses of high-precision...
Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.
News | Proton Therapy | October 25, 2020
October 25, 2020 — Treating lung cancer patients with prot...
Radiation Oncology Orchestrator (IntelliSpace Radiation Oncology) and Practice Management can reduce the time from patient referral to the start of treatment by up to half
News | Radiation Oncology | October 25, 2020
October 25, 2020 —Philips, a global leader in health technology, will showcase its latest advances in ...